Clinical Usefulness of Arbekacin.
- Author:
Jae Hoon LEE
1
;
Chang Seop LEE
Author Information
- Publication Type:Comparative Study ; In Vitro ; Review
- Keywords: Arbekacin; Methicillin-resistant Staphylococcus aureus; Glycopeptides; Alternative; Antibiotics
- MeSH: Acinetobacter baumannii; Anti-Bacterial Agents; Drug Monitoring; Enterococcus; Glycopeptides; Humans; Methicillin-Resistant Staphylococcus aureus; Pseudomonas aeruginosa
- From:Infection and Chemotherapy 2016;48(1):1-11
- CountryRepublic of Korea
- Language:English
- Abstract: Arbekacin is a broad-spectrum aminoglycoside used to treat methicillin-resistant Staphylococcus aureus (MRSA). Arbekacin has antibacterial activities against high-level gentamicin-resistant Enterococci, multidrug-resistant Pseudomonas aeruginosa, and Acinetobacter baumannii et al. Here, we reviewed in vitro data on arbekacin in Staphylococci and Gram-negative microorganisms. We also reviewed clinical studies for clinical efficacy and microbiologic efficacy data in patients with identified MRSA and suspected MRSA infections. The overall clinical efficacy ranged from 66.7% to 89.7%. The microbiologic efficacy rate ranged from 46.2% to 83%. In comparative studies between arbekacin and glycopeptides, arbekacin was similar to other glycopeptides with respect to clinical and microbiological efficacy rates. Combination trials with other antibiotics suggest that arbekacin will be a promising strategy to control Enterococcus spp. multi-drug resistant P. aeruginosa. The major adverse reaction was nephrotoxicity/hepatotoxicity, but patients recovered from most adverse reactions without any severe complications. Based on these results, arbekacin could be a good alternative to vancomycin/teicoplanin in MRSA treatment. Finally, therapeutic drug monitoring is recommended to maximize clinical efficacy and decrease nephrotoxicity.
